Back to Search Start Over

SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC

Authors :
L. Roberts
Johanna C. Bendell
Tark Kim
Sami Mahrus
Matthew Wongchenko
Guillem Argiles
Xueping Qu
A. Uyei
Kelly DuPree
Yibing Yan
Fortunato Ciardiello
Yi Shi
Source :
Annals of Oncology. 31:S229
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Details

ISSN :
09237534
Volume :
31
Database :
OpenAIRE
Journal :
Annals of Oncology
Accession number :
edsair.doi...........3cbf63f594eed2a7a3c7efd5536db07e
Full Text :
https://doi.org/10.1016/j.annonc.2020.04.047